Imugene Ltd

IMU

Company Profile

  • Business description

    Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

  • Contact

    4-6 Bligh Street
    Suite 12.01, Level 12
    SydneyNSW2000
    AUS

    https://www.imugene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    5

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,741.9026.70-0.30%
CAC 407,804.8714.600.19%
DAX 4024,304.4619.12-0.08%
Dow JONES (US)42,762.87443.131.05%
FTSE 1008,837.9126.870.30%
HKSE24,092.21299.671.26%
NASDAQ19,529.95231.511.20%
Nikkei 22538,137.09395.481.05%
NZX 50 Index12,529.4234.06-0.27%
S&P 5006,000.3661.061.03%
S&P/ASX 2008,515.7023.20-0.27%
SSE Composite Index3,396.5911.240.33%

Market Movers